# Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

> **NCT00562055** · PHASE2 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine
- **DRUG:** PNU-165442G; [S,S]-reboxetine

## Key facts

- **NCT ID:** NCT00562055
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was withdrawn due to business reasons.
- **Last updated:** 2019-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00562055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00562055, "Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00562055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*